IL264674A - - Google Patents
Info
- Publication number
- IL264674A IL264674A IL26467419A IL26467419A IL264674A IL 264674 A IL264674 A IL 264674A IL 26467419 A IL26467419 A IL 26467419A IL 26467419 A IL26467419 A IL 26467419A IL 264674 A IL264674 A IL 264674A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371680P | 2016-08-05 | 2016-08-05 | |
| PCT/US2017/045641 WO2018027203A1 (en) | 2016-08-05 | 2017-08-04 | Anti-siglec-7 antibodies for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL264674A true IL264674A (enExample) | 2019-03-31 |
| IL264674B1 IL264674B1 (en) | 2023-05-01 |
| IL264674B2 IL264674B2 (en) | 2023-09-01 |
Family
ID=61073084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264674A IL264674B2 (en) | 2016-08-05 | 2017-08-04 | Antibodies to siglec7 for cancer treatment |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11773162B2 (enExample) |
| EP (1) | EP3494142A4 (enExample) |
| JP (1) | JP7137563B2 (enExample) |
| KR (1) | KR20190035863A (enExample) |
| CN (1) | CN109790223A (enExample) |
| AU (1) | AU2017307616A1 (enExample) |
| BR (1) | BR112019002331A2 (enExample) |
| CA (1) | CA3032437A1 (enExample) |
| EA (1) | EA201990296A1 (enExample) |
| IL (1) | IL264674B2 (enExample) |
| MX (1) | MX2019001471A (enExample) |
| SG (1) | SG11201901020RA (enExample) |
| WO (1) | WO2018027203A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383614B (es) | 2015-05-21 | 2025-03-14 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EA201990296A1 (ru) | 2016-08-05 | 2019-08-30 | Аллакос, Инк. | Антитела против siglec-7 для лечения рака |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| US11447545B2 (en) | 2017-07-10 | 2022-09-20 | Innate Pharma | Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| SI3694529T1 (sl) | 2017-10-13 | 2024-10-30 | Harpoon Therapeutics, Inc. | Trispecifične beljakovine in načini uporabe |
| AU2019208025A1 (en) * | 2018-01-11 | 2020-09-03 | Allakos, Inc. | Anti-Siglec-7 antibodies having reduced effector function |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021247821A1 (en) * | 2020-06-03 | 2021-12-09 | The Wistar Institute Of Anatomy And Biology | Monoclonal antibodies against human siglec-9 and use thereof for immunotherapy |
| CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| EP4634224A1 (en) | 2022-12-14 | 2025-10-22 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| JP2025027841A (ja) * | 2023-08-17 | 2025-02-28 | 国立大学法人 東京大学 | ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| US20070244038A1 (en) | 2006-04-12 | 2007-10-18 | The Regents Of The University Of California | Methods for treating lymphocyte-associated disorders by modulation of siglec activity |
| CA2691734A1 (en) * | 2007-07-04 | 2009-01-08 | Forerunner Pharma Research Co., Ltd. | Anti-muc17 antibody |
| RU2014138474A (ru) | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
| CA2896076C (en) * | 2012-12-21 | 2022-12-06 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| EP2999717B1 (en) * | 2013-05-21 | 2018-08-08 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Treatment of mast cell related pathologies |
| CA2957502C (en) | 2014-08-07 | 2021-07-20 | Daiichi Sankyo Company, Limited | Anti-orai1 antibody |
| JP2017532025A (ja) * | 2014-09-10 | 2017-11-02 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 交差反応性ｓｉｇｌｅｃ抗体 |
| EP3341411B1 (en) * | 2015-08-28 | 2025-06-11 | Alector LLC | Anti-siglec-7 antibodies and methods of use thereof |
| EP3402516A4 (en) | 2016-01-12 | 2020-01-08 | Palleon Pharmaceuticals Inc. | USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER |
| CN108699158B (zh) * | 2016-03-08 | 2022-06-03 | 依奈特制药公司 | Siglec中和抗体 |
| EA201990296A1 (ru) | 2016-08-05 | 2019-08-30 | Аллакос, Инк. | Антитела против siglec-7 для лечения рака |
-
2017
- 2017-08-04 EA EA201990296A patent/EA201990296A1/ru unknown
- 2017-08-04 IL IL264674A patent/IL264674B2/en unknown
- 2017-08-04 US US16/323,442 patent/US11773162B2/en active Active
- 2017-08-04 KR KR1020197006520A patent/KR20190035863A/ko not_active Ceased
- 2017-08-04 EP EP17837808.9A patent/EP3494142A4/en not_active Withdrawn
- 2017-08-04 JP JP2019527783A patent/JP7137563B2/ja active Active
- 2017-08-04 MX MX2019001471A patent/MX2019001471A/es unknown
- 2017-08-04 CN CN201780060307.2A patent/CN109790223A/zh active Pending
- 2017-08-04 SG SG11201901020RA patent/SG11201901020RA/en unknown
- 2017-08-04 WO PCT/US2017/045641 patent/WO2018027203A1/en not_active Ceased
- 2017-08-04 CA CA3032437A patent/CA3032437A1/en active Pending
- 2017-08-04 BR BR112019002331A patent/BR112019002331A2/pt not_active Application Discontinuation
- 2017-08-04 AU AU2017307616A patent/AU2017307616A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019002331A2 (pt) | 2019-06-18 |
| MX2019001471A (es) | 2019-10-30 |
| JP7137563B2 (ja) | 2022-09-14 |
| IL264674B2 (en) | 2023-09-01 |
| EA201990296A1 (ru) | 2019-08-30 |
| EP3494142A1 (en) | 2019-06-12 |
| IL264674B1 (en) | 2023-05-01 |
| AU2017307616A1 (en) | 2019-02-28 |
| CA3032437A1 (en) | 2018-02-08 |
| EP3494142A4 (en) | 2020-04-01 |
| US20190194323A1 (en) | 2019-06-27 |
| CN109790223A (zh) | 2019-05-21 |
| KR20190035863A (ko) | 2019-04-03 |
| US11773162B2 (en) | 2023-10-03 |
| WO2018027203A1 (en) | 2018-02-08 |
| JP2019526622A (ja) | 2019-09-19 |
| SG11201901020RA (en) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018068177A2 (enExample) | ||
| BR122021013712A2 (enExample) | ||
| BR112019002665A2 (enExample) | ||
| BR112018004986A2 (enExample) | ||
| BR112019001429A2 (enExample) | ||
| BR212018070320U2 (enExample) | ||
| BR112019008501B1 (pt) | Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador | |
| BR112019003116B1 (pt) | Configuração de símbolo de rajada comum de uplink | |
| BR112019001236B1 (pt) | Método para executar uma função suplementar para uma consulta de linguagem natural apresentada a um aplicativo de orientação de mídia interativa | |
| BR112018076493B1 (pt) | Sistemas e métodos para detecção de posição de feixe de luz | |
| BR112018073794B1 (pt) | Partícula, método de geração da partícula, vacina ou composição farmacêutica | |
| BR112018072681B1 (pt) | Anticorpos anti-il-1r3 humanizados, fragmento ou derivado do mesmo, seu uso e composição farmacêutica | |
| BR122026002520A2 (pt) | Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno | |
| BR112019006736A2 (enExample) | ||
| BR112019003108A2 (enExample) | ||
| BR102016018018A2 (enExample) | ||
| CN303537562S (enExample) | ||
| CN303537535S (enExample) | ||
| CN303537318S (enExample) | ||
| CN303642162S (enExample) | ||
| CN303536207S (enExample) | ||
| CN303536110S (enExample) | ||
| CN303628688S (enExample) | ||
| CN303537591S (enExample) | ||
| CN303608081S (enExample) |